This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Example content

Adverse event reporting can be found at the bottom of the page

COVID-19 management:​ From patient identification to treatment selection​

Prescribing information can be found at the bottom of the page.


Join us on 18 July 2024 to hear from Dr John Bright, Respiratory Consultant discussing 'COVID-19 management:​ From patient identification to treatment selection​' followed by a live interactive Q&A.

This promotional meeting is organised and funded by Pfizer Ltd for GB HCPs and may include reference to medicines or vaccines promoted by Pfizer.  

Prescribing information can be found at the bottom of the page.


Join us on 18 July 2024 to hear from Dr John Bright, Respiratory Consultant discussing 'COVID-19 management:​ From patient identification to treatment selection​' followed by a live interactive Q&A.

This promotional meeting is organised and funded by Pfizer Ltd for GB HCPs and may include reference to medicines or vaccines promoted by Pfizer.  

Event Date18 July 2024 10:00 BSTDuration1 Hr AudienceConsultants, Nurses, Pharmacists, Specialist Registrars {{givenName}}%20{{familyName}}%20has%20shared%20a%20resource%20with%20you%3B%20please%20click%20the%20link%20below%3A%0D%0A%0D%0A{{URL}}%0D%0A%0D%0AThank%20you%2C%0D%0A{{givenName}}%20{{familyName}}
Agenda
Meeting Agenda 9:45 - 10:00Joining & Registration
10:00 - 10:45COVID-19 management:​ From patient identification to treatment selection​ John Bright - Dr
10:45 - 11:00Questions & Answers John Bright - Dr
11:00Meeting Close
Speakers
Event Speakers
John Bright, Dr
John Bright, DrRespiratory Consultant, Manchester University NHS Foundation Trust

No Biography Available.

Paxlovid®(nirmatrelvir/ritonavir)

Prescribing Information for Great Britain

PAXLOVID has received a Conditional Marketing Authorisation (CMA) in Great Britain for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.1 

A Conditional Marketing Authorisation (CMA) means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information updated as necessary. 1

References: 

1 PAXLOVID GB Summary of Product Characteristics. Pfizer Inc.

Adverse events should be reported. Reporting forms and information can be found at coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-C1D-GBR-0328. June 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​